Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The
discovery of amphotericin B and its therapeutic uses is considered one of the most important …

Major developments in research into the azole class of antifungal agents during the 1990s
have provided expanded options for the treatment of many opportunistic and endemic fungal …

Cryptococcosis is a global invasive mycosis associated with significant morbidity and
mortality. These guidelines for its management have been built on the previous Infectious …

Background Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight
per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome …

Cryptococcal meningitis is a common opportunistic infection in AIDS patients, particularly in
Southeast Asia and Africa. Cases also occur in patients with other forms of …

Cryptococcus neoformans strains classically have been grouped into two varieties that
included five serotypes known as C. neoformans variety neoformans (serotypes A, D, and …

The central nervous system (CNS) distribution and antifungal efficacy of all 4 approved
formulations of amphotericin B (AmB) were investigated in a rabbit model of hematogenous …

During the past two decades invasive fungal infections have emerged as major causes of
morbidity and mortality in immunocompromised patients. Several factors have contributed to …

Background. The standard therapy for human immunodeficiency virus (HIV)–associated
cryptococcal meningitis of amphotericin B (AmB; 0.7 mg/kg per day) plus flucytosine …

Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-
associated cryptococcal meningitis (CM). Its use is hampered by toxicities that include …